Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’news2024-10-29T20:05:18+00:00October 29th, 2024|Endpoints News|
Coya shares sink on Phase 2 Alzheimer’s data for deprioritized drugnews2024-10-29T18:26:15+00:00October 29th, 2024|Endpoints News|
Shionogi touts topline data for Covid-19 antiviral for post-exposure treatmentnews2024-10-29T17:49:42+00:00October 29th, 2024|Endpoints News|
PacBio bets on ‘inflection point’ with $500 long-read genomenews2024-10-29T17:20:46+00:00October 29th, 2024|Endpoints News|
In bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its Alzheimer’s drugnews2024-10-29T16:00:42+00:00October 29th, 2024|Endpoints News|
Two type 1 diabetes patients are insulin-free after Eledon’s immunosuppressant and an islet transplantnews2024-10-29T14:49:50+00:00October 29th, 2024|Endpoints News|
Eyepoint sells $100M in shares after unveiling eye disease data for drug-device assetnews2024-10-29T14:38:51+00:00October 29th, 2024|Endpoints News|
Novartis takes $800M MorphoSys writedown mere months after closing acquisitionnews2024-10-29T11:04:41+00:00October 29th, 2024|Endpoints News|
Lilly, J&J both unveil positive late-stage data in Crohn’s diseasenews2024-10-28T17:22:17+00:00October 28th, 2024|Endpoints News|
HOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning researchnews2024-10-28T14:00:16+00:00October 28th, 2024|Endpoints News|
